On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...

Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category. Athira Pharma, Inc. faces significant ...

Before co-founding Propel Bio Partners, Leen Kawas excelled as biotech Athira’s Chief Executive Officer (or CEO). She also ...

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in ...

On Friday, Athira Pharma Inc (ATHA) stock saw a modest uptick, ending the day at $0.61 which represents a slight increase of $0.18 or 41.86% from the prior close of $0.43. The stock opened at $0.59 ...

Vast Renewables, Theriva Biologics, and Athira Pharma are the 3 Penny Stocks to watch on November 5, 2024, based on TipRanks’ ...

Athira Pharma, Inc. ( (ATHA)) has released its Q3 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors. Athira Pharma, Inc. is a clinical-stage ...

Athira Pharma (ATHA) announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease will be presented at the 17th Annual Clinical Trials on ...

based enterprise software company EnterpriseDB (EDB). Dallas spent almost 25 years at… Read More Athira Pharma’s stock plummeted nearly 70% Wednesday after a clinical trial testing its candida ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As the U.S. stock market navigates a period of uncertainty with investors closely watching the presidential election and upcoming Federal Reserve interest rate decisions, opportunities continue to ...

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018.